-
C Ray Therapeutics (Chengdu) Co., Ltd Congratulates Partner Biokin Pharmaceutical on NMPA IND Approval of First Proprietary ARC Drug [177Lu]-BL-ARC001
C Ray Therapeutics (Chengdu) Co.,Ltd proudly congratulates its strategic partner, Biokin Pharmaceutical, on receiving implied approval from the...
넶99 2025-12-11 -
C RAY Therapeutics Supports Mednovo’s Phase III Clinical Trial with First Patient Dosed for Lutetium [Lu-177] Oxodotreotide Injection
On August 22, 2025, Mednovo Medical Technology Group Co., Ltd. (“Mednovo”) successfully administered the first patient in the Phase III clinical trial of its Class III radiotherapeutic, Lutetium [Lu-177] Oxodotreotide Injection.
넶111 2025-08-26 -
Top 10 Highlights of the Year at C Ray Therapeutics
As one year gives way to the next, a new chapter unfolds.
넶11 2025-12-31 -
C Ray's JPM Week: Connecting the Global Ecosystem, Advancing the Industry Future
The J.P. Morgan Healthcare Conference will be held from January 12 to 15, 2026.
넶20 2025-12-16 -
C Ray Expands Theranostics Platform with New Lu-177 and F-18 Production Lines
On the fast track of radiopharmaceutical R&D and production, C Ray remains steadfastly client-centric, continuously strengthening its infrastructure and radionuclide capabilities.
넶34 2025-12-03 -
Domestically Developed Innovative ARC Enters Clinical Stage, Ushering in the Era of China's Self-Developed Radiopharmaceuticals
On November 4, the official website of the Drug Clinical Trial Registration and Information Publicity Platform showed that Baili Tianheng has registered a clinical trial for Lutetium[177Lu]-BL-A...
넶53 2025-12-03 -
EANM 2025 | Connecting Global Innovation, C Ray Accelerates Its Globalization Journey
On October 8 local time, the 2025 European Association of Nuclear Medicine (EANM) Annual Congress concluded successfully in Barcelona, Spain.
넶50 2025-12-03
